117 related articles for article (PubMed ID: 12718261)
1. [Report of the 6th German Interdisciplinary Congress of Intensive and Emergency Medicine. Initial experiences with the new anti-infective drug drotrecogin alfa (activated) in septic shock].
Krankenpfl J; 2003; 41(1-3):27-9. PubMed ID: 12718261
[No Abstract] [Full Text] [Related]
2. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2011 Dec; 12(6):443-9. PubMed ID: 22185191
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
Rice TW; Bernard GR
Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
[TBL] [Abstract][Full Text] [Related]
5. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy].
Haas I
Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015
[No Abstract] [Full Text] [Related]
6. Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin resistant Staphylococcus aureus infection.
Haddadin DW; Samnani IQ; Moorman JP
South Med J; 2006 Nov; 99(11):1295-6. PubMed ID: 17195430
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Strongyloides stercoralis hyperinfection-associated septic shock and acute respiratory distress syndrome with drotrecogin alfa (activated) in a renal transplant recipient.
Huston JM; Eachempati SR; Rodney JR; Cayci C; Fusco D; Mathew M; Shou J; Goldstein MJ; Kapur S; Barie PS
Transpl Infect Dis; 2009 Jun; 11(3):277-80. PubMed ID: 19392733
[TBL] [Abstract][Full Text] [Related]
8. The last Xigris® survivor.
Barie PS
Surg Infect (Larchmt); 2011 Dec; 12(6):423-5. PubMed ID: 22185189
[No Abstract] [Full Text] [Related]
9. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
10. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
Crum NF; Groff HL; Parrish JS; Ring W
Clin Infect Dis; 2004 Dec; 39(11):e122-3. PubMed ID: 15578351
[TBL] [Abstract][Full Text] [Related]
11. Continuing challenges of sepsis research.
Crowther MA; Marshall JC
JAMA; 2001 Oct; 286(15):1894-6. PubMed ID: 11597294
[No Abstract] [Full Text] [Related]
12. Rapidly fatal bacteremic pneumonia caused by Klebsiella pneumoniae with K1 hypermucoviscosity phenotype in a previously healthy young man receiving levofloxacin treatment.
Chuang TY; Lin CJ; Chi CL; Liu AY; Lee SW; Lin TL; Wang JT; Hsueh PR
J Microbiol Immunol Infect; 2009 Oct; 42(5):439-41. PubMed ID: 20182675
[TBL] [Abstract][Full Text] [Related]
13. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
Sajan I; Da-Silva SS; Dellinger RP
J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
[TBL] [Abstract][Full Text] [Related]
14. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis].
Spies C; Otter H; Zuckermann-Becker H; Kox WJ
Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
Brueckmann M; Wizenmann J; Hoffmann U; Seeger M; Bewig B
Thromb Res; 2003 Mar; 109(5-6):259-63. PubMed ID: 12818248
[TBL] [Abstract][Full Text] [Related]
16. [PROWESS--milestone in lowering sepsis mortality].
Reinhart K
Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
[No Abstract] [Full Text] [Related]
17. [Endogenous anticoagulant therapy for sepsis. Success and failure].
Wiedermann CJ
Internist (Berl); 2007 May; 48(5):537-42, 544. PubMed ID: 17390117
[TBL] [Abstract][Full Text] [Related]
18. [Progress in therapy of infection].
Müller-Werdan U; Buerke M; Werdan K
Internist (Berl); 2003 Dec; 44(12):1531-40. PubMed ID: 14689196
[No Abstract] [Full Text] [Related]
19. Treatment of septic shock and use of drotrecogin alfa (activated) in children.
Marraro GA
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):769-72. PubMed ID: 19735218
[No Abstract] [Full Text] [Related]
20. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.
Bachli EB; Vavricka SR; Walter RB; Leschinger MI; Maggiorini M
Intensive Care Med; 2003 Feb; 29(2):337. PubMed ID: 12594601
[No Abstract] [Full Text] [Related]
[Next] [New Search]
